GU Cancers 2019 | Updated analysis of KEYNOTE-199: pembrolizumab for mCRPC previously treated with docetaxel

Emmanuel Antonarakis

Emmanuel Antonarakis, MBBCh, of Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA. He discusses the updated analysis of the KEYNOTE-199 study (KEYNOTE-199), which investigated pembrolizumab for metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.

Share this video  
Similar topics